"The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more ...

Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 ...

As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...

Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...

Novo Nordisk is the company that makes the Ozempic and Wegovy drugs, part of the wildly popular GLP-1 class of drugs that have proven effective in reducing weight and treating diabetes. Demand has ...

Nutritionists say there’s an easy, natural and cheaper way to get the same results as prescription weight loss drugs.

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Amid the rise of gut health and GLP-1 drugs in the UK, Potina is making high-fibre banana oat milks for improved children's ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...